Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Drug

EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer

Fineline Cube Jan 5, 2023

EOC Pharma, a biotech company operating in the US and China, has announced that its...

Company Deals

HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds

Fineline Cube Jan 5, 2023

China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds,...

Company Deals R&D

Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration

Fineline Cube Jan 5, 2023

US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced...

Policy / Regulatory

China’s NHC and NATCM Launch Integrated Pain Management Pilot Plan

Fineline Cube Jan 5, 2023

The National Health Commission (NHC) and the National Administration of Traditional Chinese Medicine (NATCM) have...

Company Deals

Zhongchao Partners with Natco Pharma to Distribute Drugs in China

Fineline Cube Jan 5, 2023

Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced multiple agreements with...

Company Deals

By-Health to Establish Nutrition Research Center with Shanghai Institute

Fineline Cube Jan 5, 2023

China-based By-Health Co., Ltd. (SHE: 300146) is set to establish a “scientific nutrition research and...

Company Deals

CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA

Fineline Cube Jan 4, 2023

China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to...

Company Drug

Transcenta’s TST003 Receives Clinical Trial Approval in China and US

Fineline Cube Jan 4, 2023

China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...

Company Drug

Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications

Fineline Cube Jan 4, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Sihuan’s Hui Sheng Bio Completes Series A+ Financing for Diabetes Pipeline

Fineline Cube Jan 4, 2023

China – based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced the successful completion...

Company Drug

HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP

Fineline Cube Jan 4, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...

Company Drug

RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer

Fineline Cube Jan 4, 2023

China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...

Company Deals

Apeloa and Simcere Partner for CDMO Services and R&D Collaboration

Fineline Cube Jan 4, 2023

China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739)...

Company Deals

Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5

Fineline Cube Jan 4, 2023

China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia...

Company Deals

Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds

Fineline Cube Jan 4, 2023

Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully...

Company

Everest Medicines Outlines Strategic Plans for Expansion and Growth

Fineline Cube Jan 4, 2023

China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for...

Company

Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D

Fineline Cube Jan 4, 2023

Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of...

Company Drug

Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors

Fineline Cube Jan 4, 2023

China – based Jiangxi Jemincare Group has announced that it has received approval from the...

Company Drug

Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases

Fineline Cube Jan 4, 2023

China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has...

Company Drug

Staidson’s Anti-C5a Monoclonal Antibody STSA-1002 Accepted for NMPA Review

Fineline Cube Jan 3, 2023

China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced that the clinical trial filing...

Posts pagination

1 … 560 561 562 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.